Responses
Clinical/translational cancer immunotherapy
Original research
Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06)
Compose a Response to This Article
Other responses
No responses have been published for this article.
